Arkansas 2023 Regular Session

Arkansas House Bill HB1562

Introduced
3/6/23  
Refer
3/6/23  
Report Pass
3/9/23  
Engrossed
3/14/23  
Refer
3/14/23  
Report Pass
3/30/23  
Enrolled
4/6/23  
Chaptered
4/11/23  

Caption

To Amend The Naloxone Access Act; To Increase Availability And Accessibility Of An Opioid Antagonist; And To Declare An Emergency.

Impact

The bill revises Arkansas Code § 20-13-1804, expanding the categories of individuals who can prescribe, dispense, or supply naloxone. This includes not only healthcare professionals but also friends, family members, and employees of various organizations, highlighting a shift towards a more community-based approach to overdose prevention. By increasing the scope of who can obtain and administer naloxone without fear of liability, the bill seeks to ensure that more people can intervene in overdose situations, potentially saving lives.

Summary

House Bill 1562 aims to amend the Naloxone Access Act in Arkansas to enhance the availability and accessibility of opioid antagonists, particularly naloxone, which is critical for reversing opioid-related overdoses. This amendment comes as a response to the ongoing opioid crisis that has exacerbated since the COVID-19 pandemic, leading to record levels of overdose deaths. The legislature recognizes the necessity for individuals at risk and their loved ones to have better access to life-saving treatments, thereby addressing one of the significant public health challenges facing the state.

Sentiment

The sentiment surrounding HB 1562 is largely supportive from public health advocates and lawmakers concerned about the opioid epidemic. They argue that expanding access to naloxone can help mitigate the increasing number of overdose deaths and improve overall community safety. Opponents, if any, have not been prominently noted in the discussions, indicating a strong consensus on the urgency and importance of the bill.

Contention

While the bill is primarily viewed positively, discussions may arise regarding the implications of granting immunity to individuals administering naloxone. The legislation could lead to questions about appropriate training and the risk of misuse. Nevertheless, the strong emphasis on accessibility and the emergency designation of the bill suggests a prioritized focus on immediate public health needs over potential long-term concerns.

Companion Bills

No companion bills found.

Similar Bills

HI HB310

Relating To Opioid Antagonists.

CO HB1037

Substance Use Disorders Harm Reduction

MI HB5077

Health: pharmaceuticals; distribution of naloxone under the administration of opioid antagonist act to any individual; provide for. Amends title & secs. 103 & 107 of 2019 PA 39 (MCL 15.673 & 15.677) & adds sec. 106.

CA SB472

Pupil health: opioid overdose reversal medication.

MI HB4366

Health: pharmaceuticals; distribution of naloxone under the administration of opioid antagonist act to any individual; provide for. Amends title & secs. 103 & 107 of 2019 PA 39 (MCL 15.673 & 15.677) & adds sec. 106. TIE BAR WITH: HB 4365'23

MS SB2336

Prevention of overdoses; authorize administration of opioid antagonists by certain persons, provide immunity to.

MS SB2442

Emergency Response and Overdose Prevention Act; amend to expand the distribution and use of opioid antagonists.

MS HB1137

Opioid antagonists; authorize community organizations and others to receive and administer.